Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Elderly Patients
100%
Immune Checkpoint Inhibitors
100%
Immune Checkpoint Inhibitor Monotherapy
100%
Confidence Interval
57%
Overall Survival Rate
14%
Long-term Survival
14%
Lung Cancer
14%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Treatment Options
14%
Cancer Study
14%
Okayama
14%
Median Survival Time
14%
Objective Response Rate
14%
Long-lasting Effect
14%
First-line Therapy
14%
Median Progression-free Survival
14%
Limited Information
14%
Anticancer Therapy
14%
Immune-related
14%
Super-elderly Patient
14%
Pembrolizumab
14%
Programmed Death-ligand 1 Expression
14%
Immune-related Adverse Events
14%
Medicine and Dentistry
Monotherapy
100%
Elderly Patient
100%
Non Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
100%
Survival Rate
12%
Overall Survival
12%
Lung Cancer
12%
Long Term Survival
12%
Immunotherapy
12%
Progression Free Survival
12%
Cancer Treatment
12%
Median Survival Time
12%
Programmed Death 1 Ligand 1
12%
Pembrolizumab
12%
Immune-Related Adverse Events
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Monotherapy
100%
Immune Checkpoint Inhibitor
100%
Adverse Event
12%
Lung Cancer
12%
Survival Rate
12%
Immunotherapy
12%
Progression Free Survival
12%
Overall Survival
12%
Median Survival Time
12%
Long Term Survival
12%
Programmed Death 1 Ligand 1
12%
Pembrolizumab
12%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Median Survival Time
12%
Survival Rate
12%
Anticancer
12%
Progression Free Survival
12%
Overall Survival
12%
Long Term Survival
12%
Pembrolizumab
12%